FLARAXIN Capsules are antiviral, anti-inflammatory, anti-cancer, anti-fungal, immunomodulatory, stimulate the production of interferon, reduce allergic reactions, suppress the development of pathogenic microflora and strengthen the protective properties of the body.
FLARAXIN Capsules are antitumoral, antibacterial, antiviral herbal medication, which stimulates the production of alpha, beta and gamma interferons, tumor necrosis and acts as a protector of normal cells during the chemotherapy process. It possesses anti-oxidant as well as anti-inflamatory properties as well as being moderately hypotensive. It can be used effectively for the treatment of inflammatory diseases of the digestive and intestinal organs. It reduces toxins and overall intoxication, and is safe in application. In most cases manages to achieve the regression of tumours and destroy metastasises.
FLARAXIN prevents relapse of the disease. It is actively used in the complex treatment of gastrointestinal cancer. Is otherwise also used to treat viral hepatitis B, C, D, E, to restore the leukocyte blood formula, with herpes and cytomegalovirus infection and multiple sclerosis. It effectively destroys viruses and bacteria that cause infection and improves capillary blood supply. Reduces the level of toxins in the blood. Demonstrates radionuclides.
When combined with chemotherapy and radiotherapy, the drug enhances the efficiency of treatments against cancerous cells and reduces damage to normal cells.
FLARAXIN is compatible with most drugs, except ones containing iron.
FLARAXIN Capsules are effective against:
Malignant neoplasms: brain (glioma, ependrymoma, oligodendroglioma, etc.); skin cancer (melanoma, melanoblastoma, basal cell carcinoma, etc.); lung cancer; mammary cancer; cancer of the pharynx and larynx; esophageal stomach cancer; colon cancer; kidney cancer (adenocarcinoma); bladder cancer; prostate cancer; cancer of the female reproductive organs (uterus, cervix, ovaries); Hodgkin’s disease; and blood cancer;
Benign tumors: uterine fibroids, mastophathy, prostate adenoma, polyposis of various organs, skin papilloma, etc.;
Autoimmune diseases: multiple sclerosis, scleroderma, systemic lupus erythematosus, autoimmune thyroiditis, atopic dermatitis, rheumatoid arthritis, etc.;
Infectious diseases: viral hepatitis, herpes, cytomgalovirus, mononucleosis, urogenital infections, influenza (SARS), adenovirus infections, complex therapy of tuberculosis, etc.;
Prophylactics of infectious and oncological diseases.
FLARAXIN normalizes the immunological background in cancer patients; Normalizes the ratio of immune-competent Cd4 / Cd8 cells (helper suppressors) and increases the number of natural killers (NK-cells). Immunobiochemical research has established FLARAXIN’s ability to bind with cancer proteins, causing micro-denturizion damage to them.
The cancerostatic effect is caused due to the influence of FLARAXIN on the metabolism of cancerous cells, causing their death. Positive therapeutic effects in patients with advanced forms of cancer include restraining of metastatic activity and elimination of autoimmune disorders; substantially improving the quality of the lives of patient of this category. FLARAXIN can be used in various clinical and morphological forms of malignant neoplasms, treatment of benign tumours, and as a cancerostatic and anti-reccurent medication.
The combining of FLARAXIN with chemotherapy and radiotherapy is clinically approved, it is as well effective to use FLARAXIN in adjuvant and non-adjuvant therapy. In the former case the conditions for an effective surgical operation are created. While in the latter case, the need to continue prophylactic chemotherapeutic treatments ceases. FLARAXIN actively binds to pathological immune complexes and is able to prevent the progression of autoimmune diseases in the pathogenesis, in which immune complexes are formed (cirrhosis, hepatitis, chronic nephritis, etc.). The aforementioned properties of FLARAXIN grant you the ability to use it in the treatment of viral infections of the CNS and slow viral infections (which include AIDS, multiple sclerosis, etc.).
1 capsule contains 150 mg of lyophilized phenol powder of herbal origin, tannin, vitamins C, E, potassium iodide. As well as kelp extract obtained through application of vacuum-condensing technology.
FLARAXIN Tablets should not be used during pregnancy. If there is an acute need for the use of FLARAXIN Tablets during lactation, breastfeeding should be discontinued.
Interaction with other medicine
To date, there has been no clinically significant interaction of FLARAXIN Capsules with any other methods of treatment of bacterial and viral infections or with antibiotics.
At the moment, there are no known cases of overdose of this remedy.
Flaraxin is contraindicated in pregnant women, children under 7 years of age and those who are hypersensitive to the drug. With ulcer 12 duodenal ulcer, stomach ulcer and small intestine.
Must be stored in a dry, dark and unreachable to children place at a temperature between 20° C to 25° C and humidity levels under 70%.
Form of Issue
Capsules of 150mg, 30 pcs. packaged.